Inflammatory bowel disease of the elderly: frequently asked questions (FAQs)

Am J Gastroenterol. 2011 Nov;106(11):1889-97. doi: 10.1038/ajg.2011.271. Epub 2011 Aug 23.


The growing recognition of the older inflammatory bowel disease (IBD) patient is heightened by the entry of the 77.2 million baby boomers who will turn 65 beginning of 2011. It is anticipated that this will occur at a rate of 10,000 per day or 4 million per year for the next 19 years. The management of IBD in this population is complex because of problems with co-morbidities, polypharmacy, impaired mobility, and cognition, as well as difficult social and financial issues. This review focuses on the older IBD patient's unique concerns and provides guidance in their diagnosis and management.

Publication types

  • Review

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / therapeutic use
  • Antibodies, Monoclonal / therapeutic use
  • Diagnosis, Differential
  • Humans
  • Immunologic Factors / therapeutic use
  • Inflammatory Bowel Diseases / diagnosis*
  • Inflammatory Bowel Diseases / epidemiology
  • Inflammatory Bowel Diseases / metabolism
  • Inflammatory Bowel Diseases / therapy*
  • Mesalamine / therapeutic use
  • Middle Aged


  • Adrenal Cortex Hormones
  • Anti-Bacterial Agents
  • Antibodies, Monoclonal
  • Immunologic Factors
  • Mesalamine